Pimozide, which is clinically used to treat schizophrenia, has been reported to inhibit STAT5 phosphorylation in chronic myelogenous leukemia, T-cell prolymphocytic leukemia, osteosarcoma, and breast cancer [10,30–33]. This evidence concerns the gene STAT5A and T-cell prolymphocytic leukemia.